The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 14, 2020

Filed:

Nov. 09, 2018
Applicant:

Bavarian Nordic A/s, Kvistgaard, DK;

Inventors:

Cédric Cheminay, Munich, DE;

Robin Steigerwald, Munich, DE;

Paul Chaplin, Grafelfing, DE;

Assignee:

Bavarian Nordic A/S, Kvistgaard, DK;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/155 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); C07K 14/005 (2006.01); C12N 15/86 (2006.01); C12Q 1/6851 (2018.01);
U.S. Cl.
CPC ...
A61K 39/155 (2013.01); A61K 39/12 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); C12Q 1/6851 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/543 (2013.01); A61K 2039/57 (2013.01); A61K 2039/575 (2013.01); C07K 2319/00 (2013.01); C12N 2710/24142 (2013.01); C12N 2710/24143 (2013.01); C12N 2710/24171 (2013.01); C12N 2760/18534 (2013.01); C12N 2760/18571 (2013.01);
Abstract

Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant MVA vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein. Also provided herein are products, methods and uses thereof, e.g., suitable to affect an immune response in a subject, or suitable to diagnose an RSV infection, as well as to determine whether a subject is at risk of recurrent RSV infection.


Find Patent Forward Citations

Loading…